PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Amerise Biosciences reported audited standalone results for FY2026. Revenue from operations grew to Rs. 25.52 lakhs from Rs. 18.80 lakhs in the prior year (FY2025), a ~35.7% increase. Profit before tax improved to Rs. 2.06 lakhs (vs Rs. 0.76 lakhs), and net profit after tax rose to Rs. 1.61 lakhs (vs Rs. 0.57 lakhs), representing a ~182.5% PAT growth year-on-year. EPS stands at Rs. 0.02. Total assets declined to Rs. 742.19 lakhs from Rs. 846.33 lakhs, primarily due to a reduction in non-current loans. Cash and cash equivalents surged significantly to Rs. 59.19 lakhs (from Rs. 2.22 lakhs), driven by large inflows from investment redemptions and loan repayments. Other equity remains negative at Rs. -121.10 lakhs. Statutory auditor Bipin & Co. issued an Unmodified Opinion (clean report) with no qualifications.
The company shows strong double-digit revenue and PAT growth for the year, with significantly improved cash position, though absolute profitability remains thin. The clean audit opinion is reassuring for investors, but the small base and negative equity warrant caution.